Skip to main content

PIRS

Stock
Health Care
Biotechnology

Performance overview

PIRS Price
Price Chart

Forward-looking statistics

Beta
1.79
Risk
98.08%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Pieris Pharmaceuticals Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of the Anticalin class of biotherapeutics. Anticalin proteins are engineered versions of lipocalins, human proteins that naturally bind, store, and transport a wide spectrum of molecules. The Company's clinical pipeline consists of immuno-oncology, or IO, bispecifics in partnership with collaborators, including S095012 (also referred to as PRS-344) targeting PD-L1 and 4-1BB, SGN-BB228 (also referred to as PRS-346) targeting CD228 and 4-1BB, and BOS-342 (also referred to as PRS-342) targeting GPC3 and 4-1BB. Geographically, all the operations of the firm function through the region of the United States.

Company info

SectorHealth Care
IndustryBiotechnology
Employees95
Market cap$13.5M

Fundamentals

Enterprise value$1.3M
Revenue$20.9M
Revenue per employee—
Profit margin-114.12%
Debt to equity0.00

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$12.11
Dividend per share—
Revenue per share$16.66
Avg trading volume (30 day)$1M
Avg trading volume (10 day)$2M
Put-call ratio—

Macro factor sensitivity

Growth-1.6
Credit+6.2
Liquidity+2.6
Inflation-5.2
Commodities-3.2
Interest Rates-1.3

Valuation

Dividend yield0.00%
PEG Ratio-68.00
Price to sales0.86
P/E Ratio-68.00
Enterprise Value to Revenue0.06
Price to book0.63

Upcoming events

Next earnings dayMarch 30, 2024
Next dividend day—
Ex. dividend day—

News

Pieris Pharmaceuticals (PIRS) Upgraded to Strong Buy: Here's Why

Pieris Pharmaceuticals (PIRS) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Investment Research (September 25, 2023)
3 Biotech Stocks to Watch Now

Biotech companies develop new medicines, vaccines, or medical devices. They use advanced technologies and medical science to do so.

Benzinga (October 12, 2021)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free